Jorge Di Paola

Profile picture
Professor of Pediatrics, Division Chief, Hematology & Oncology. Elizabeth Finney McDonnell Endowed Chair in Pediatric Hematology Oncology
Associate Director, Medical Scientist Training Program (MSTP)
School of MedicineHematology and Oncology



  • MD, University of Buenos Aires1990


  • Pediatric Residency, Hospital Nacional de Pediatría “Juan P. Garrahan”1991 - 1994
  • Pediatric Hematology-Oncology Fellowship, Children’s Hospital of Orange County1995 - 1997
  • Pediatric Residency 2nd & 3rd years, Children’s Hospital of Orange County1997 - 1999
  • Hematology-Oncology Fellowship 3rd year, Children’s Hospital of Orange County1999 - 2000

Licensure and Board Certification

  • CA, California Medical License
  • IA, Iowa Medical License
  • CO, Colorado Medical License
  • 2000 - PresAmerican Board of Pediatric (Hematology & Oncology)
  • 2020 - PresMO, Missouri Medical License

Honors and Awards

  • Scholar, Children’s Health Research Center (CHRC-K12-NIH) University of Iowa2001 - 2003
  • Hemophilia and Thrombosis Research Society Investigator in Hemostasis Award2003
  • James C. Taylor Teaching Award, University of Iowa, Department of Pediatrics2003
  • The Inaugural Postle Family Chair in Pediatric Cancer and Blood Disorders, Children's Hospital Colorado2008 - 2019
  • Best Doctors in America2009
  • Vice-President, President Elect: Hemostasis and Thrombosis Research Society (HTRS)2010
  • Best Doctors in America2011
  • Best Doctors in America2012
  • Excellence in Mentoring and Advising Award, Research/Scholarship, University of Colorado School of Medicine2012
  • Chair, Von Willebrand Factor Subcommittee, International Society of Thrombosis and Hemostasis (ISTH)2013 - 2016
  • Frank Oski Memorial Lectureship Award, American Society of Pediatric Hematology Oncology2013
  • Chair, State of the Art Symposium, American Society of Hematology (ASH)2014
  • Co-Vice Chair, Gordon Research Conference in Hemostasis2014
  • Elected Member-At-Large of the Leadership Committee of the Arteriosclerosis Thrombosis and Vascular Biology (ATVB) Council of the American Heart Association (AHA)2014
  • Arthur R. Thompson Inaugural Lectureship, Puget Sound Blood Center, University of Washington2015
  • Best Doctors in America2015
  • Co-Chair (with James Morrissey, PhD), Gordon Research Conference in Hemostasis2016
  • Co-Chair (with Selina Luger, MD), Education Program American Society of Hematology Annual 58th Annual Meeting2016
  • Scientific Advisory Board, National Rare Diseases Center (CIBERER), Spain2016 - Pres
  • Visiting Professor, Aflac Cancer and Blood Disorders Center Fall Research Conference, Emory University2016
  • Best Doctors in America2017
  • Elected Member, American Association of Physicians (AAP)2017
  • Elected Member International Society of Thrombosis and Haemostasis (ISTH) Council, Class of 20242018
  • Elected Vice President (President Elect) American Society of Pediatric Hematology Oncology (ASPHO)2018
  • Ralph Gruppo Inaugural Lectureship, Cincinnati Children's Hospital2018
  • Elizabeth Finney McDonnell Endowed Chair in Pediatric Hematology Oncology, Washington University in St. Louis2020 - Pres
  • Elected Member American Pediatric Society2020

Recent Publications view all (137)

Publication Co-Authors

  1. Evaluation for Bleeding Disorders in Suspected Child Abuse. Pediatrics. 2022;150(4). PMID:36180615 
  2. Ristocetin dependent cofactor activity in von Willebrand disease diagnosis: Limitations of relying on a single measure. Res Pract Thromb Haemost. 2022;6(7):e12807. PMCID:PMC9637542  PMID:36381287 
  3. Germline ETV6 mutation promotes inflammation and disrupts lymphoid development of early hematopoietic progenitors. Exp Hematol. 2022. PMID:35803545 
  4. Apolipoprotein A-I, elevated in trauma patients, inhibits platelet activation and decreases clot strength. Platelets. 2022;1-13. PMID:35659185 
  5. Enhanced VWF clearance in Low VWF pathogenesis - limitations of VWFpp/VWF:Ag ratio and clinical significance. Blood Adv. 2022. PMID:35523118 
  6. Molecular pathogenesis and heterogeneity in type 3 VWD families in U.S. Zimmerman Program. J Thromb Haemost. 2022. PMID:35343054 
  7. Genetics of Inherited thrombocytopenias. Blood. 2022. PMID:35167650 
  8. Single Cell Transcriptional Analysis of Human Endothelial Colony Forming Cells from Patients with Low VWF Levels. Blood. 2022. PMID:35143643 
  9. Whole-exome analysis of adolescents with low VWF and heavy menstrual bleeding identifies novel genetic associations. Blood Adv. 2022;6(2):420-428. PMCID:PMC8791588  PMID:34807970 
  10. Isotopically nonstationary 13C metabolic flux analysis in resting and activated human platelets. Metab Eng. 2022;69:313-322. PMID:34954086 
  11. Bleeding assessment tools in the diagnosis of VWD in adults and children: a systematic review and meta-analysis of test accuracy. Blood Adv. 2021;5(23):5023-5031. PMID:34597385 
  12. Diagnostic approach to the patient with a suspected inherited platelet disorder: Who and how to test. J Thromb Haemost. 2021;19(9):2127-2136. PMID:34347927 
  13. Interleukin-7 Reverses Lymphopenia and Improves T-Cell Function in Coronavirus Disease 2019 Patient With Inborn Error of Toll-Like Receptor 3: A Case Report. Crit Care Explor. 2021;3(7):e0500. PMCID:PMC8322565  PMID:34345826 
  14. Negatively charged nanoparticles of multiple materials inhibit shear-induced platelet accumulation. Nanomedicine. 2021;35:102405. PMID:33932591 
  15. Antithrombin deficiency: A pediatric disorder. Thromb Res. 2021;202:45-51. PMID:33725558 
  16. VWF antigen levels are associated with burden of rare nonsynonymous variants in the VWF gene. Blood. 2021. PMID:33556167 
  17. von Willebrand disease: proposing definitions for future research. Blood Adv. 2021;5(2):565-569. PMCID:PMC7839375  PMID:33496750 
  18. Specifications of the variant curation guidelines for ITGA2B/ITGB3: ClinGen Platelet Disorder Variant Curation Panel. Blood Adv. 2021;5(2):414-431. PMCID:PMC7839359  PMID:33496739 
  19. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. Blood Adv. 2021;5(1):280-300. PMCID:PMC7805340  PMID:33570651 
  20. Management of elective procedures in low von Willebrand factor patients in the LoVIC study. J Thromb Haemost. 2020. PMID:33346399 
  21. Platelet activation contributes to hypoxia-induced inflammation Am J Physiol Lung Cell Mol Physiol. 2020. doi:10.1152/ajplung.00519.2020  PMID:33264579 
  22. ETV6 Thrombocytopenia and Predisposition to Leukemia 2020. PMID:33226740 
  23. ETV6 germline mutations cause HDAC3/NCOR2 mislocalization and upregulation of interferon response genes. JCI Insight. 2020;5(18). PMID:32841218 
  24. Hemostasis vs. homeostasis: Platelets are essential for preserving vascular barrier function in the absence of injury or inflammation. Proc Natl Acad Sci U S A. 2020. PMID:32929010 
  25. Pathologic Shear and Elongation Rates Do Not Cause Cleavage of Von Willebrand Factor by ADAMTS13 in a Purified System. Cell Mol Bioeng. 2020;13(4):379-390. PMCID:PMC7479076  PMID:32952737 
  26. Platelet α-granules are required for occlusive high-shear-rate thrombosis. Blood Adv. 2020;4(14):3258-3267. PMCID:PMC7391145  PMID:32697818 
  27. Hypermethioninemia Leads to Fatal Bleeding and Increased Mortality in a Transgenic I278T Mouse Model of Homocystinuria. Biomedicines. 2020;8(8). PMCID:PMC7459533  PMID:32722248 
  28. ETV6-related thrombocytopenia and platelet dysfunction. Platelets. 2020;1-3. PMID:32406789 
  29. Glanzmann thrombasthenia: genetic basis and clinical correlates. Haematologica. 2020;105(4):888-894. PMCID:PMC7109743  PMID:32139434 
  30. Platelet activation in experimental murine neonatal pulmonary hypertension Physiol Rep. 2020. doi:10.14814/phy2.14386  PMID:32163236 
  31. An international survey to inform priorities for new guidelines on von Willebrand disease. Haemophilia. 2019. PMID:31769905 
  32. Behavior, body composition, and vascular phenotype of homocystinuric mice on methionine-restricted diet or enzyme replacement therapy. FASEB J. 2019;33(11):12477-12486. PMCID:PMC6902697  PMID:31450979 
  33. A mathematical model of coagulation under flow identifies factor V as a modifier of thrombin generation in hemophilia A. J Thromb Haemost. 2019. PMID:31562694 
  34. Turbulent Flow Promotes Cleavage of VWF (von Willebrand Factor) by ADAMTS13 (A Disintegrin and Metalloproteinase With a Thrombospondin Type-1 Motif, Member 13). Arterioscler Thromb Vasc Biol. 2019;39(9):1831-1842. PMID:31291760 
  35. TNF-α-driven inflammation and mitochondrial dysfunction define the platelet hyperreactivity of aging. Blood. 2019;134(9):727-740. PMCID:PMC6716075  PMID:31311815 
  36. ETV6-related thrombocytopenia and leukemia predisposition. Blood. 2019;134(8):663-667. PMCID:PMC6706811  PMID:31248877 
  37. Illustrated State-of-the-Art Capsules of the ISTH 2019 Congress in Melbourne, Australia. Res Pract Thromb Haemost. 2019;3(3):431-497. PMCID:PMC6611378  PMID:31294333 
  38. Pro-inflammatory cytokine blockade attenuates myeloid expansion in a murine model of rheumatoid arthritis. Haematologica. 2019. PMID:31101752 
  39. Increased galactose expression and enhanced clearance in patients with low von Willebrand factor. Blood. 2019;133(14):1585-1596. PMID:30770394 
  40. Loss of fibrinogen in zebrafish results in an asymptomatic embryonic hemostatic defect and synthetic lethality with thrombocytopenia. J Thromb Haemost. 2019;17(4):607-617. PMCID:PMC6443434  PMID:30663848 
  41. Recovery and analysis of transcriptome subsets from pooled single-cell RNA-seq libraries. Nucleic Acids Res. 2019;47(4):e20. PMCID:PMC6393243  PMID:30496484 
  42. One over PAR or one under PAR: vive la différence. Blood. 2018;132(19):2007-2008. PMCID:PMC6236467  PMID:30409895 
  43. Antiplatelet Effect of Ketorolac in Children After Congenital Cardiac Surgery. World J Pediatr Congenit Heart Surg. 2018;9(6):651-658. PMID:30322371 
  44. Genomics and transcriptomics of megakaryocytes and platelets: Implications for health and disease. Res Pract Thromb Haemost. 2018;2(4):630-639. PMCID:PMC6178711  PMID:30349880 
  45. Identification and characterization of novel mutations implicated in congenital fibrinogen disorders. Res Pract Thromb Haemost. 2018;2(4):800-811. PMCID:PMC6178649  PMID:30349899 
  46. NBEAL2 mutations and bleeding in patients with gray platelet syndrome. Platelets. 2018;29(6):632-635. PMID:29869935 
  47. A local and global sensitivity analysis of a mathematical model of coagulation and platelet deposition under flow. PLoS One. 2018;13(7):e0200917. PMCID:PMC6062055  PMID:30048479 
  48. Significant gynecological bleeding in women with low von Willebrand factor levels. Blood Adv. 2018;2(14):1784-1791. PMCID:PMC6058240  PMID:30042144 
  49. Chitinase 3-like-1 promotes intrahepatic activation of coagulation through induction of tissue factor in mice. Hepatology. 2018;67(6):2384-2396. PMCID:PMC5992002  PMID:29251791 
  50. von Willebrand Disease: Diagnostic Strategies and Treatment Options. Pediatr Clin North Am. 2018;65(3):527-541. PMID:29803281 
  51. GAS6/TAM Pathway Signaling in Hemostasis and Thrombosis. Front Med (Lausanne). 2018;5:137. PMCID:PMC5954114  PMID:29868590 
  52. Effects of anti-β2GPI antibodies on VWF release from human umbilical vein endothelial cells and ADAMTS13 activity. Res Pract Thromb Haemost. 2018;2(2):380-389. PMCID:PMC5974922  PMID:30046742 
  53. The small-molecule MERTK inhibitor UNC2025 decreases platelet activation and prevents thrombosis. J Thromb Haemost. 2018;16(2):352-363. PMCID:PMC5858881  PMID:29045015 
  54. Evaluation of a microfluidic flow assay to screen for von Willebrand disease and low von Willebrand factor levels. J Thromb Haemost. 2018;16(1):104-115. PMCID:PMC5794217  PMID:29064615 
  55. Novel insights into the clinical phenotype and pathophysiology underlying low VWF levels. Blood. 2017;130(21):2344-2353. PMCID:PMC5881608  PMID:28916584 
  56. Editor's Highlight: Pulmonary Vascular Thrombosis in Rats Exposed to Inhaled Sulfur Mustard. Toxicol Sci. 2017;159(2):461-469. PMCID:PMC5837673  PMID:28962529 
  57. Limit of detection and threshold for positivity of the Centers for Disease Control and Prevention assay for factor VIII inhibitors. J Thromb Haemost. 2017;15(10):1971-1976. PMCID:PMC5716470  PMID:28795528 
  58. The ENTPD1 promoter polymorphism -860 A > G (rs3814159) is associated with increased gene transcription, protein expression, CD39/NTPDase1 enzymatic activity, and thromboembolism risk. FASEB J. 2017;31(7):2771-2784. PMCID:PMC6137499  PMID:28302652 
  59. Peptides derived from MARCKS block coagulation complex assembly on phosphatidylserine. Sci Rep. 2017;7(1):4275. PMCID:PMC5487340  PMID:28655899 
  60. Tamoxifen Suppresses Platelet Activation-Supported Angiogenesis and Metastasis. Arterioscler Thromb Vasc Biol. 2017;37(4):611-612. PMCID:PMC5873979  PMID:28330945 
  61. Microangiopathic hemolytic anemia due to ADAMTS-13 loss in idiopathic systemic capillary leak syndrome: reply. J Thromb Haemost. 2017;15(4):827-828. PMID:28182327 
  62. A microfluidic model of hemostasis sensitive to platelet function and coagulation. Cell Mol Bioeng. 2017;10(1):3-15. PMCID:PMC5435378  PMID:28529666 
  63. Microangiopathic hemolytic anemia due to ADAMTS-13 loss in idiopathic systemic capillary leak syndrome. J Thromb Haemost. 2016;14(12):2353-2355. PMCID:PMC6553946  PMID:27622772 
  64. Variable bleeding phenotype in an Amish pedigree with von Willebrand disease. Am J Hematol. 2016;91(10):E431-5. PMCID:PMC5031525  PMID:27414491 
  65. Survey of the anti-factor IX immunoglobulin profiles in patients with hemophilia B using a fluorescence-based immunoassay. J Thromb Haemost. 2016;14(10):1931-1940. PMCID:PMC5083216  PMID:27501440 
  66. Platelet clearance via shear-induced unfolding of a membrane mechanoreceptor. Nat Commun. 2016;7:12863. PMCID:PMC5052631  PMID:27670775 
  67. Platelet abnormalities in a family with von Willebrand disease type 2B (V1316M) and association with bleeding score. Haemophilia. 2016;22(5):e455-8. PMID:27385556 
  68. Mutations in the D'D3 region of VWF traditionally associated with type 1 VWD lead to quantitative and qualitative deficiencies of VWF. Thromb Res. 2016;145:112-8. PMCID:PMC5951169  PMID:27533707 
  69. Spontaneous 8bp Deletion in Nbeal2 Recapitulates the Gray Platelet Syndrome in Mice. PLoS One. 2016;11(3):e0150852. PMCID:PMC4780761  PMID:26950939 
  70. Platelet type von Willebrand disease and registry report: communication from the SSC of the ISTH. J Thromb Haemost. 2016;14(2):411-4. PMID:26882161 
  71. Paris-Trousseau: evidence keeps pointing to FLI1. Blood. 2015;126(17):1973-4. PMID:26494917 
  72. ETV6 mutations define a new cancer predisposition syndrome. Oncotarget. 2015;6(19):16830-1. PMCID:PMC4627276  PMID:26219557 
  73. Variable content of von Willebrand factor mutant monomer drives the phenotypic variability in a family with von Willebrand disease. Blood. 2015;126(2):262-9. PMCID:PMC4497966  PMID:26019279 
  74. Microfluidic technology as an emerging clinical tool to evaluate thrombosis and hemostasis. Thromb Res. 2015;136(1):13-9. PMCID:PMC4910695  PMID:26014643 
  75. Platelet-dependent von Willebrand factor activity. Nomenclature and methodology: communication from the SSC of the ISTH. J Thromb Haemost. 2015;13(7):1345-50. PMCID:PMC5576173  PMID:25858564 
  76. Evaluation of von Willebrand factor phenotypes and genotypes in Hemophilia A patients with and without identified F8 mutations. J Thromb Haemost. 2015;13(6):1036-42. PMCID:PMC4512234  PMID:25780857 
  77. Germline mutations in ETV6 are associated with thrombocytopenia, red cell macrocytosis and predisposition to lymphoblastic leukemia. Nat Genet. 2015;47(5):535-538. PMCID:PMC4631613  PMID:25807284 
  78. Diagnostic approach to von Willebrand disease. Blood. 2015;125(13):2029-37. PMCID:PMC4375103  PMID:25712990 
  79. Characterization of the anti-factor VIII immunoglobulin profile in patients with hemophilia A by use of a fluorescence-based immunoassay. J Thromb Haemost. 2015;13(1):47-53. PMCID:PMC4383171  PMID:25354263 
  80. Genetic basis of congenital platelet disorders. Hematology Am Soc Hematol Educ Program. 2014;2014(1):337-42. PMID:25696876 
  81. Evaluating Familial Essential Tremor with Novel Genetic Approaches: Is it a Genotyping or Phenotyping Issue? Tremor Other Hyperkinet Mov (N Y). 2014;4:258. PMCID:PMC4219111  PMID:25374765 
  82. Factor XIII activity mediates red blood cell retention in venous thrombi. J Clin Invest. 2014;124(8):3590-600. PMCID:PMC4109540  PMID:24983320 
  83. Understanding congenital platelet disorders. Clin Adv Hematol Oncol. 2014;12(7):461-3. PMID:25322327 
  84. FVIII/VWF ratio is not a reliable predictor of VWD in children. Pediatr Blood Cancer. 2014;61(5):936-9. PMID:24281894 
  85. Platelets join the world of "Omics". Blood. 2014;123(16):2446-7. PMID:24744250 
  86. A study of prospective surveillance for inhibitors among persons with haemophilia in the United States. Haemophilia. 2014;20(2):230-7. PMCID:PMC4519821  PMID:24261612 
  87. A novel mutation in PLP1 causes severe hereditary spastic paraplegia type 2. Gene. 2014;533(1):447-50. PMID:24103481 
  88. Discovery of Mer specific tyrosine kinase inhibitors for the treatment and prevention of thrombosis. J Med Chem. 2013;56(23):9693-700. PMCID:PMC3962266  PMID:24219778 
  89. The effect of factor VIII deficiencies and replacement and bypass therapies on thrombus formation under venous flow conditions in microfluidic and computational models. PLoS One. 2013;8(11):e78732. PMCID:PMC3827262  PMID:24236042 
  90. Abnormal megakaryocyte development and platelet function in Nbeal2(-/-) mice. Blood. 2013;122(19):3349-58. PMCID:PMC3953091  PMID:23861251 
  91. Prophylactic efficacy and pharmacokinetically guided dosing of a von Willebrand factor/factor VIII concentrate in adults and children with von Willebrand's disease undergoing elective surgery: a pooled and comparative analysis of data from USA and European Union clinical trials. Blood Transfus. 2013;11(4):533-40. PMCID:PMC3827397  PMID:23736911 
  92. Quantitative trait locus linkage analysis in a large Amish pedigree identifies novel candidate loci for erythrocyte traits. Mol Genet Genomic Med. 2013;1(3):131-141. PMCID:PMC3775389  PMID:24058921 
  93. Comparison of clot-based, chromogenic and fluorescence assays for measurement of factor VIII inhibitors in the US Hemophilia Inhibitor Research Study. J Thromb Haemost. 2013;11(7):1300-9. PMCID:PMC4477744  PMID:23601690 
  94. SHPing in different directions in platelet production. Blood. 2013;121(20):4018-9. PMID:23682031 
  95. No increase in bleeding identified in type 1 VWD subjects with D1472H sequence variation. Blood. 2013;121(18):3742-4. PMCID:PMC3643771  PMID:23520336 
  96. Limited physical therapy utilization protocol does not affect impairment and disability in Workers' Compensation patients after rotator cuff repair: a short-term follow-up study. J Shoulder Elbow Surg. 2013;22(3):409-17. PMID:22939405 
  97. New developments in the treatment of pediatric hemophilia and bleeding disorders. Curr Opin Pediatr. 2013;25(1):23-30. PMID:23274430 
  98. Tissue factor signals airway epithelial basal cell survival via coagulation and protease-activated receptor isoforms 1 and 2. Am J Respir Cell Mol Biol. 2013;48(1):94-104. PMCID:PMC3547080  PMID:23065128 
  99. Sources of variability in platelet accumulation on type 1 fibrillar collagen in microfluidic flow assays. PLoS One. 2013;8(1):e54680. PMCID:PMC3552855  PMID:23355889 
  100. Dysregulated coagulation associated with hypofibrinogenaemia and plasma hypercoagulability: implications for identifying coagulopathic mechanisms in humans. Thromb Haemost. 2012;108(3):516-26. PMCID:PMC3627352  PMID:22836883 
  101. Validation of Nijmegen-Bethesda assay modifications to allow inhibitor measurement during replacement therapy and facilitate inhibitor surveillance. J Thromb Haemost. 2012;10(6):1055-61. PMCID:PMC4477703  PMID:22435927 
  102. F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race/ethnicity. Haemophilia. 2012;18(3):375-82. PMID:22103590 
  103. Making a diagnosis of VWD. Hematology Am Soc Hematol Educ Program. 2012;2012:161-7. PMCID:PMC5873588  PMID:23233576 
  104. Characterization of collagen thin films for von Willebrand factor binding and platelet adhesion. Langmuir. 2011;27(22):13648-58. PMID:21967679 
  105. Thrombocytopenias due to gray platelet syndrome or THC2 mutations. Semin Thromb Hemost. 2011;37(6):690-7. PMID:22102272 
  106. Presurgical pharmacokinetic analysis of a von Willebrand factor/factor VIII (VWF/FVIII) concentrate in patients with von Willebrand's disease (VWD) has limited value in dosing for surgery. Haemophilia. 2011;17(5):752-8. PMID:21689209 
  107. The pharmacokinetic diversity of two von Willebrand factor (VWF)/ factor VIII (FVIII) concentrates in subjects with congenital von Willebrand disease. Results from a prospective, randomised crossover study. Thromb Haemost. 2011;106(2):279-88. PMID:21725579 
  108. Mutations in NBEAL2, encoding a BEACH protein, cause gray platelet syndrome. Nat Genet. 2011;43(8):738-40. PMCID:PMC6050511  PMID:21765413 
  109. Homozygosity mapping with SNP arrays confirms 3p21 as a recessive locus for gray platelet syndrome and narrows the interval significantly. Blood. 2011;117(12):3430-4. PMCID:PMC3069679  PMID:21263149 
  110. Challenges and innovations in the treatment of bleeding disorders. Thromb Res. 2011;127 Suppl 1:S1-2. PMID:21056903 
  111. Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor. Blood. 2010;116(2):280-6. PMCID:PMC2910611  PMID:20231421 
  112. Recombinant factor IX for clinical and research use. Semin Thromb Hemost. 2010;36(5):498-509. PMID:20632248 
  113. The application of genetics to inherited bleeding disorders. Haemophilia. 2010;16 Suppl 5:35-9. PMID:20590854 
  114. Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring. J Thromb Haemost. 2010;8(4):730-6. PMCID:PMC2855866  PMID:20398185 
  115. Bleeding symptoms and laboratory correlation in patients with severe von Willebrand disease. Haemophilia. 2009;15(4):918-25. PMID:19473418 
  116. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost. 2009;7(3):413-20. PMID:19143924 
  117. Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients. J Thromb Haemost. 2008;6(8):1319-26. PMID:18503631 
  118. Evaluation of thromboelastography for monitoring recombinant activated factor VII ex vivo in haemophilia A and B patients with inhibitors: a multicentre trial. Blood Coagul Fibrinolysis. 2008;19(4):276-82. PMID:18469548 
  119. Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of haemophilia patients with inhibitors. Haemophilia. 2008;14(3):466-75. PMID:18282155 
  120. Biologic response to subcutaneous and intranasal therapy with desmopressin in a large Amish kindred with Type 2M von Willebrand disease. Haemophilia. 2008;14(3):539-48. PMID:18312368 
  121. VWD type 1: a calculated diagnosis. Blood. 2008;111(8):3919-20. PMID:18434968 
  122. Critical role for the mitochondrial permeability transition pore and cyclophilin D in platelet activation and thrombosis. Blood. 2008;111(3):1257-65. PMCID:PMC2214770  PMID:17989312 
  123. ReFacto and Advate: a single-dose, randomized, two-period crossover pharmacokinetics study in subjects with haemophilia A. Haemophilia. 2007;13(2):124-30. PMID:17286764 
  124. Application of current knowledge to the management of bleeding events during immune tolerance induction. Haemophilia. 2006;12(6):591-7. PMID:17083508 
  125. Role of FcRgamma and factor XIIIA in coated platelet formation. Blood. 2005;106(13):4146-51. PMCID:PMC1895237  PMID:16105983 
  126. Index of suspicion. Pediatr Rev. 2005;26(12):461-6. PMID:16327027 
  127. Determinants of bleeding severity in von Willebrand disease. Curr Hematol Rep. 2005;4(5):345-9. PMID:16131434 
  128. Platelet glycoprotein I(b)alpha and integrin alpha2 beta1 polymorphisms: gene frequencies and linkage disequilibrium in a population diversity panel. J Thromb Haemost. 2005;3(7):1511-21. PMID:15978109 
  129. The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B. Blood. 2005;105(2):518-25. PMID:15383463 
  130. Product selection issues in the management of hemophilia B. Blood Coagul Fibrinolysis. 2004;15 Suppl 2:S17-8. PMID:15322454 
  131. Deep venous thrombosis and Turner syndrome. J Pediatr Hematol Oncol. 2004;26(4):272. PMID:15087960 
  132. Breakpoint of a balanced translocation (X:14) (q27.1;q32.3) in a girl with severe hemophilia B maps proximal to the factor IX gene. J Thromb Haemost. 2004;2(3):437-40. PMID:15009460 
  133. Role of the adapter protein SLP-76 in GPVI-dependent platelet procoagulant responses to collagen. Blood. 2002;100(8):2839-44. PMID:12351393 
  134. Immune thrombocytopenic purpura. Pediatr Clin North Am. 2002;49(5):911-28. PMID:12430619 
  135. Current therapy for rare factor deficiencies. Haemophilia. 2001;7 Suppl 1:16-22. PMID:11240614 
  136. Low platelet alpha2beta1 levels in type I von Willebrand disease correlate with impaired platelet function in a high shear stress system. Blood. 1999;93(11):3578-82. PMID:10339461 
  137. Sequential study of the histopathology and cellular and humoral immune response during the development of an autoimmune orchitis in Wistar rats. Am J Reprod Immunol. 1989;20(2):44-51. PMID:2803528 
Last updated: 12/05/2022
© 2022 by Washington University in St. Louis
One Brookings Drive, St. Louis, MO 63130